13 research outputs found
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy
Background
Recent studies have reported weight gain in virologically suppressed persons living with human immunodeficiency virus (PLWH) switched from older antiretroviral therapy (ART) to newer integrase strand transfer inhibitor (INSTI)–based regimens. In this study, we investigated whether weight gain differs among treatment-naive PLWH starting INSTI-based regimens compared to other ART regimens.
Methods
Adult, treatment-naive PLWH in the Vanderbilt Comprehensive Care Clinic cohort initiating INSTI-, protease inhibitor (PI)–, and nonnucleoside reverse transcriptase inhibitor (NNRTI)–based ART between January 2007 and June 2016 were included. We used multivariable linear mixed-effects models to generate marginal predictions of weights over time, adjusting for baseline clinical and demographic characteristics. We used restricted cubic splines to relax linearity assumptions and bootstrapping to generate 95% confidence intervals.
Results
Among 1152 ART-naive PLWH, 351 initiated INSTI-based regimens (135 dolutegravir, 153 elvitegravir, and 63 raltegravir), 86% were male, and 49% were white. At ART initiation, median age was 35 years, body mass index was 25.1 kg/m2, and CD4+ T-cell count was 318 cells/μL. Virologic suppression at 18 months was similar between different ART classes. At all examined study time points, weight gain was highest among PLWH starting dolutegravir. At 18 months, PLWH on dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTIs (P < .05), and 0.5 kg for elvitegravir (P < .05). PLWH starting dolutegravir also gained more weight at 18 months compared to raltegravir (3.4 kg) and PIs (4.1 kg), though these differences were not statistically significant.
Conclusions
Treatment-naive PLWH starting dolutegravir-based regimens gained significantly more weight at 18 months than those starting NNRTI-based and elvitegravir-based regimens
Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response
Pregnancy has been associated with a decreased risk of HIV disease progression in the highly active antiretroviral therapy (HAART) era. The effect of timing of HAART initiation relative to pregnancy on maternal virologic, immunologic and clinical outcomes has not been assessed.We conducted a retrospective cohort study from 1997–2005 among 112 pregnant HIV-infected women who started HAART before (N = 12), during (N = 70) or after pregnancy (N = 30).0.01). There were no statistical differences in rates of HIV disease progression between groups.HAART initiation during pregnancy was associated with better immunologic and virologic responses than initiation after pregnancy
Recommended from our members
Association of ‘(tropical) ataxic neuropathy’ with HTLV-II
Jamaican Neuropathy of the ataxic type (tropical ataxic neuropathy [TAN] and spastic type (tropical spastic paraparesis [TSP]) have been recognized for over a century in Jamaica. The recent association of TSP with HTLV-I (TSP/HAM) is now well established. We now present evidence for a possible association between a TAN-like illness with HTLV-II in four females aged 34–49. All presented with ataxic gait and all four have prominent mental changes. Three of the four also have minor motor deficits with urinary frequency and two have nocturnal leg cramps. All have serum antibody and all had PCR evidence of HTLV-II infection. Antibody to HTLV-II is present in CSF from two subjects. The distinctive picture of prominent ataxia and altered mental status in these subjects contrasts with a predominantly myelopathic picture seen in TSP/HAM
Demographic and clinical characteristics of the study population (N = 112).
<p>Note: HAART: highly active antiretroviral therapy. IQR: interquartile range. CD4+ lymphocyte count nadir: the lowest CD4+ lymphocyte count while in care. ADE: AIDS-defining event. IDU: history of injection drug use as a risk factor for HIV infection acquisition. HCV: hepatitis C virologic status prior to first HAART initiation. NA: not available. ART: antiretroviral therapy. PI: protease inhibitor. NNRTI: non-nucleoside reverse transcriptase inhibitor.</p>*<p>The reference group.</p>a<p>Continuous data were compared by Kruskal-Wallis test. Categorical data were compared by 2-sided Fisher's exact test.</p
Estimated rate of HIV-1 RNA and CD4+ lymphocyte change.
<p>The estimated rate of HIV-1 RNA decline and CD4+ lymphocyte increase (small circles) and 95% confidence interval (vertical bars) by pregnancy group over the 6 months following HAART initiation, adjusted for baseline CD4+ lymphocyte count and HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, prior ADE, prior use of non-HAART ART, HAART type, prior pregnancies, and date of HAART start. Horizontal lines represent <i>p-</i>values in a pair-wise comparison (women who started HAART during pregnancy as a reference). Left panel: The estimated rate of HIV-1 RNA decline: −0.32 log<sub>10</sub> copies/mL (95% CI −1.45, 0.81) in women who started HAART before pregnancy, −0.35 log<sub>10</sub> copies/mL (95% CI −0.57, −0.13) in women who started HAART during pregnancy, and 0.10 log<sub>10</sub> copies/mL (95% CI −0.46, 0.66) in women who started HAART after pregnancy. Right panel: The estimated rate of CD4+ lymphocyte increase: estimates were 155.8 cells/mm<sup>3</sup> (95% CI −107.6, 419.2) in women who started HAART before pregnancy, 183.8 cells/mm<sup>3</sup> (95% CI 110.8, 256.9) in women who started HAART during pregnancy, and −70.8 cells/mm<sup>3</sup> (95% CI −326.8, 185.3) in women who started HAART after pregnancy.</p
Multivariable linear mixed effects models: independent predictors of HIV-1 RNA levels (log<sub>10</sub> copies/mL) and CD4+ lymphocyte counts (cells/mm<sup>3</sup>) during 6 months following first HAART initiation<sup>*</sup><sup>&</sup>.
<p>Note: 95% CI: 95% confidence interval. HAART: highly active antiretroviral therapy. CD4+ lymphocyte count nadir: the lowest CD4+ lymphocyte count while in care. ADE: AIDS-defining event. Non-HAART ART: non-HAART antiretroviral therapy.</p>*<p>Mixed effect model adjusted for baseline CD4+ lymphocyte count and HIV-1 RNA level, age, race, CD4+ lymphocyte count nadir, prior ADE, prior use of non-HAART ART, HAART type, prior pregnancies, and date of HAART initiation.</p>&<p>The reference group was women who started HAART during pregnancy.</p>**<p>Interaction terms are equal to the difference in slopes of HIV-1 RNA and CD4+ lymphocyte changes between women who started HAART during pregnancy and those who started HAART before or after pregnancy.</p
Kaplan-Meier survival curve of progression to new AIDS-defining event or death by timing of HAART initiation.
<p>The numbers of women at risk each year are also given.</p